Shots:

• Curamys to get the non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology (which is used for the production of proteins) and ExPERT platform. MaxCyte will receive platform licensing fees and program-related revenue
• MaxCyte's ExPERT instrument portfolio, an electroporation technology used for complex cell engineering that provides high-end performance to enable biological and cellular therapies
• Curamys' goal is to transform biomedical sciences through the use of cell fusion-based technologies by assisting in the identification of genetic factors underlying a variety of rare diseases with unknown medical causes

Ref: Globenewswire | Image: Compass Therapeutics